The quality of medical products for cardiovascular diseases: a gap in global cardiac care.
Ngan Thi DoKhonsavath BellinghamPaul N NewtonCéline CailletPublished in: BMJ global health (2021)
The data suggest that SF cardiovascular products are likely to be a serious public health problem that has received limited attention. We do not suggest that 15.4% of cardiovascular medicines are SF, and our findings highlight the need for more research with robust methodology to provide more accurate prevalence estimates in order to inform policy and implement measures to ensure the quality of cardiovascular medicines and devices within the supply chain. Ensuring that CVD medical products are of good quality would help ensure effectiveness and that the benefits of therapy are realised in the prevention and treatment of CVDs.
Keyphrases
- public health
- healthcare
- quality improvement
- cardiovascular disease
- randomized controlled trial
- risk factors
- working memory
- type diabetes
- left ventricular
- electronic health record
- machine learning
- atrial fibrillation
- mass spectrometry
- chronic pain
- bone marrow
- artificial intelligence
- replacement therapy
- health insurance
- global health
- cardiovascular events
- affordable care act